PDS Biotech Q1 net loss $7.3M ($0.13/sh); VERSATILE-003 amended with PFS endpoint

PDS Biotechnology Corp

Net loss $7.3M ($0.13 per share) vs $8.5M ($0.21) YoY; revenue not reported.
R&D expenses $3.5M, down from $5.8M; cash $21.7M at March 31.
VERSATILE-003 Phase 3 amended to add PFS as interim primary endpoint, reducing enrollment; patients already enrolled continue.
PDS01ADC mCRC trial: 77.8% ORR and ~85% 24-month survival; mCRPC trial: median PFS 9.6 months.
New US and Japan patents granted for PDS0101, extending market protection into 2040s.

item 2.02item 9.01

Source: SEC EDGAR

accession 0001140361-26-020934

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.